Effects of nafamostat mesilate, a protease Inhibitor, on ischemia/reperfusion-induced kidney injury in mice

• Autores: Jae Chul Lee
• Localización: European Journal of anatomy, ISSN-e 1136-4890, Vol. 21, Nº. 4, 2017, págs. 279-286
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Ischemia is induced when blood flow to an organ is interrupted, and re-establishing blood flow is essential to prevent ongoing hypoxic injury, although it paradoxically imparts further injury. Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used in patients undergoing hemodialysis who are at a high risk of bleeding. To determine the protective effect of NM on ischemia-reperfusion injury (IRI) in a mouse renal IRI model, NM was administered as a pre- and post-treatment or during ischemia reperfusion and compared to a control group. Mice were bilaterally nephrectomized and subjected to 40 min of renal pedicle occlusion followed by 24 h reperfusion. NM (240 μg/kg) significantly improved kidney function and lowered serum creatinine and blood urea nitrogen levels. Consistently, NM inhibited collagen formation in kidney tissues. NM treatment attenuated the effects of ischemia/reperfusion on kidney tissues and significantly inhibited activation of Toll-like receptor 4, nuclear factor kappa-light-chain-enhancer of activated B cells-phospho-65 (NF- kB-p65), phospho-inhibitor of NF-κβa, and inducible nitric oxide synthase (iNOS). NM treatment also decreased expression of Bcl-2, Caspase-3 and Bax in kidney tissues, which has been linked with induction of apoptosis in kidney tissues. Our studies suggest that NM may be a novel therapeutic agent to prevent and treat kidney IRI, in which iNOS and/or NF-κβ are upregulated. The exact regulatory mechanism and its functional significance require further elucidation.